Skip to main content
. 2003 Nov;134(2):351–359. doi: 10.1046/j.1365-2249.2003.02289.x

Fig. 3.

Fig. 3

HLA-B27-restricted CTL lines with specificity for the HLA-B*2705 derived nonapeptide LRRYLENGK can be obtained from AS patients. (a) Specific lysis of T2-B*2705 target cells pulsed with the peptide LRRYLENGK, RRYLENGKETL and two control peptides by an HLA-B27-restricted peptide specific CTL line generated from PBMC of patient AS22. T2-B*2705 cells pulsed with control peptides (influenza NP 383–391 (SRYWAIRTR) and an HLA-A3 binding peptide (KIFSEVTPK)) were not killed. T2 target cells pulsed with LRRYLENGK, T2 alone and T2-B*2705 alone served as controls. (b) Specific lysis of T2-B*2705 target cells with and without peptides by two HLA-B27 restricted peptide specific CTL lines generated from PBMC of patient AS12 and SFMC of patient AS7. (c) Specific lysis of C1R-B*2705 target cells with and without peptides by an HLA-B27 restricted CTL line generated from PBMC of patient AS11. All experiments were performed in triplicate.